When you’re first diagnosed with inflammatory bowel disease (IBD), one of the first questions is whether it can be cured. The short answer is no – there is currently no cure for Crohn’s disease or ulcerative colitis (UC). However, the goal of modern treatment is to achieve remission, a state in which inflammation is controlled and the gut lining can heal. Understanding what remission means and how it differs from a cure can help set realistic expectations and guide decisions about long-term management.
What does ‘cure’ mean in IBD?
A cure would mean the disease is permanently eliminated and will never return, requiring no further treatment or monitoring. In IBD, this would involve reversing the underlying immune dysfunction that drives inflammation in the digestive tract. Despite significant advances in treatment, no therapy can currently achieve this. Crohn’s disease and ulcerative colitis are chronic conditions requiring ongoing management even when symptoms are absent.
This does not mean people with IBD cannot live well. Many achieve long periods of remission where they feel healthy, experience no symptoms, and have no active gut inflammation. The focus of care has shifted from simply controlling symptoms to achieving deeper control of the disease process itself.
What is remission?
Remission is the primary goal of IBD treatment. It refers to a state in which disease activity is reduced or eliminated, inflammation is controlled, and the gut lining can heal. Remission exists on a spectrum, with different types reflecting different levels of disease control.
Clinical remission
Clinical remission means symptoms such as diarrhoea, abdominal pain, rectal bleeding, and urgency have resolved or significantly improved. This is the most immediate and noticeable form of remission and was historically the main treatment target. However, clinical remission does not always mean inflammation has stopped. Some people continue to have active gut inflammation even when feeling well, a situation that can lead to complications over time.
Endoscopic remission
Endoscopic remission, also known as mucosal healing, means inflammation visible during colonoscopy has resolved. The bowel lining appears normal or near-normal, with no active ulcers, erosions, or significant inflammation. Achieving endoscopic remission is associated with better long-term outcomes, including fewer hospitalisations, reduced need for surgery, and lower relapse rates.
Histological remission
Histological remission is the deepest level of control and refers to the absence of inflammation at the microscopic level. Even when the bowel lining looks normal during endoscopy, biopsy samples can still show signs of ongoing immune activity. Achieving histological remission is increasingly recognised as important, though it remains more challenging to reach and is not yet a standard target in all treatment protocols.
Biochemical remission
Biochemical remission refers to normalisation of inflammatory markers in blood or stool, such as C-reactive protein (CRP) or faecal calprotectin. These markers reflect inflammation levels and can be monitored without invasive procedures. Biochemical remission often correlates with mucosal healing and is a useful tool for tracking disease activity between endoscopies.
Why remission is not the same as cure
Remission represents control of the disease, not elimination. Even in deep remission with no visible or microscopic inflammation, the underlying immune dysfunction remains. Without ongoing treatment, inflammation is likely to return. The immune system in people with IBD continues to have the potential to react inappropriately to triggers such as gut bacteria, stress, infections, or dietary changes.
The duration and stability of remission vary widely. Some remain in remission for many years, whilst others experience relapses despite ongoing treatment. The unpredictable nature of IBD means even well-controlled disease requires regular monitoring and, in many cases, indefinite medication.
What influences the likelihood of remission?
Several factors influence whether someone achieves and maintains remission. Early and aggressive treatment is associated with better outcomes, particularly when started soon after diagnosis and before significant complications develop. The type and location of disease also play a role, with some forms of Crohn’s disease being more difficult to control.
Adherence to prescribed medication is critical. Many relapses occur when people stop or reduce treatment during periods when they feel well, underestimating ongoing inflammatory activity beneath the surface. Lifestyle factors, including diet, stress management, sleep, and smoking cessation, also contribute to long-term stability, though they cannot replace medical therapy.
Can surgery cure IBD?
For people with ulcerative colitis, surgical removal of the colon and rectum can eliminate the disease, as UC only affects the large intestine. This procedure, known as a proctocolectomy, is sometimes performed when medication fails or complications arise. However, surgery is not considered a cure as it permanently alters the digestive system and carries its own risks and lifestyle adjustments.
In Crohn’s disease, surgery is not curative because the condition can affect any part of the digestive tract and often recurs in other areas after removal of diseased tissue. Surgery is typically reserved for complications such as strictures, fistulas, or abscesses and is used in combination with medical therapy to maintain remission.
The role of treatment in achieving remission
Modern IBD treatment aims to achieve the deepest level of remission possible using a range of therapies, including aminosalicylates, corticosteroids, immunomodulators, biologics, and small molecule drugs. These medications work by suppressing the immune system, reducing inflammation, and allowing the gut lining to heal. Treatment is often tailored to the individual, taking into account disease severity, location, and response to previous therapies.
Diet and nutrition play a supporting role. Whilst no specific diet can cure IBD or replace medication, certain dietary strategies may help reduce symptoms and support gut health. Omega-3 fatty acids, for example, have anti-inflammatory properties and may support mucosal healing, though they are not a substitute for medical treatment.
Practical takeaways
- Understand that remission is the goal, not cure. IBD is a chronic condition requiring ongoing management.
- Work with your healthcare team to achieve the deepest level of remission possible, including endoscopic and biochemical control.
- Continue prescribed medication even when you feel well. Stopping treatment can lead to relapse.
- Monitor your condition regularly through blood tests, stool tests, and endoscopy as recommended by your gastroenterologist.
- Support long-term stability with a balanced diet, adequate sleep, stress management, and avoidance of smoking.
- Be aware that surgery may be an option for complications or severe disease, but it is not a cure in most cases.
Conclusion
There is currently no cure for Crohn’s disease or ulcerative colitis, but achieving and maintaining remission is a realistic and meaningful goal. Remission represents control of inflammation and healing of the gut lining, allowing many people with IBD to live well and avoid complications. The focus of modern treatment is on achieving deep, sustained remission through medication, monitoring, and lifestyle support. With the right approach, long-term stability is possible.
References
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031
- Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-1201. doi:10.1053/j.gastro.2011.06.054
- Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338. doi:10.1038/ajg.2015.233
- Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619-1635. doi:10.1136/gutjnl-2012-302830
- Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014;20(3):564-575. doi:10.1097/01.MIB.0000437986.00190.71
- Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590-1605. doi:10.1016/S0140-6736(12)60026-9
- Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619. doi:10.1016/S0140-6736(12)60150-0
- Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965-990. doi:10.1016/j.crohns.2012.09.003
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.